From exciting next-generation therapies to a 10-minute-long standing ovation, Osnat Hakimi and Yael Gruenbaum-Cohen share highlights and key takeaways from #ASCO2024. Thanking our colleagues, friends, and collaborators who shared their insights with us. Read more below: Nectin Therapeutics KAHR-Medical Ltd. SOPHiA GENETICS Leal Health Pangea Biomed Portal Innovations, LLC Inocras Inc. Shasqi Biofidelity Novartis Eli Lilly and Company AstraZeneca MENARINI Group AbbVie Astellas Pharma BTIG
aMoon Fund
Venture Capital and Private Equity Principals
Ra'anana, Israel 9,098 followers
Accelerating Cure
About us
aMoon is a global HealthTech and Life Sciences investment fund based in Israel. As Israel’s largest HealthTech fund, with $1.1 billion AUM, we partner with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare. Together with our portfolio companies, we work tirelessly to advance solutions that will help people live healthier, better lives. We harness our unique team of over 50 scientists, physicians and entrepreneurs and our global network of investors and industry leaders to build bridges between our portfolio companies and global tech, finance and medical research hubs to help entrepreneurs turn their vision into reality. Through our Velocity Fund we invest in companies pursuing disruptive, cutting-edge technologies as early as venture formation through Series A. Our Growth Fund invests in later-stage companies that are either generating revenue in growth rounds, pre-IPO rounds or in pivotal clinical trials.
- Website
-
http://amoon.fund/
External link for aMoon Fund
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 11-50 employees
- Headquarters
- Ra'anana, Israel
- Type
- Partnership
- Founded
- 2016
- Specialties
- Healthcare, Biotechnology, Financial Services, Fund Management, Investment Management, Venture Capital, Biotechnology, Biopharmaceuticals, Digital Health, Medical Devices, Company Building, Early Stage Investments, Late Stage Investments, Israel, Life Sciences, and Health IT
Locations
-
Primary
Get directions
34 Jerusalem Road
Ra'anana, Israel 4350108, IL
Employees at aMoon Fund
Updates
-
Last week, we had the pleasure of hosting Brian Alexander, Amit Agrawal, Bhooshi De Silva, Cecilia Schott, David Peoples, and Ross Muken, alongside 40 key opinion leaders from the T&D sector for an insightful panel on how #enablingtechnologies are revolutionizing care. Read our takeaways below! Yair Schindel, MD, MBA Tomer Berkovitz Yaron Daniely Reut Shema Yael Gruenbaum-Cohen Avital Adler, PhD #acceleratingcure
DIA Eats World: How Enabling Technologies Revolutionize Care
amoon.fund
-
aMoon Fund reposted this
An Israel-based company, backed by aMoon and Israel Biotech Fund, is looking for a stellar CEO 💫 To apply, reach out to: [email protected]
-
-
An Israel-based company, backed by aMoon and Israel Biotech Fund, is looking for a stellar CEO 💫 To apply, reach out to: [email protected]
-
-
Congratulations to Biolojic Design, Ltd. on their exciting collaboration with Merck KGaA, Darmstadt, Germany! Todd Sone Yael Gruenbaum-Cohen Avital Adler, PhD Osnat Hakimi
We’re excited to announce our collaboration with Merck KGaA, Darmstadt, Germany. Our teams will be leveraging our clinically validated, AI-driven platform to design potential best-in-class multi-specific antibodies for the treatment of cancer and immunological diseases, including antibody-drug conjugates (ADCs) against novel therapeutic targets. You can read more about our collaboration here: https://bit.ly/4e3tHKT. EMD Serono, Inc. #AI #drugdiscovery #ADCs #Oncology #Immunology
-
It was a pleasure to host the Israeli Society for HealthTech fellowship cohort at our office last week and discuss the future of healthtech #innovation! Hedva Voliovitch M.D, Ph.D, M.B.A Chaim Martin Roy Wiesner Yael Gruenbaum-Cohen Vered Gigi, PhD Ohad Hollander Yaniv Sadka Tamar Farfel-Becker Adam Kotzen David Reichman Nissan Elimelech
Last week our #ISoHTech fellowship cohort visited aMoon Fund, a global healthtech and life science investment fund based in Raanana. 🔵 Roy Wiesner, Partner at aMoon Velocity, gave us an introduction to aMoon’s mission in transforming healthcare. 🔵 Dr. Vered Gigi, PhD, Principal at aMoon, and Ohad Hollander, Associate at aMoon Velocity, shared their professional experience and discussed approaches to evaluating opportunities, touching on aspects that were fascinating and new for our group. 🔵 Dr. Yael Gruenbaum-Cohen, Partner and Head of aMoon Alpha, untangled the different investment paths for platforms vs products when supporting breakthrough technologies in healthcare. 🔵 Yaniv Sadka, Associate at aMoon Velocity, gave us a remarkable lesson in pitching, fundraising and engineering to enhance the impact of a revolutionary product. 🔵 Dr. Tamar Farfel-Becker, Principal, and Adam Kotzen, Associate at aMoon Growth, revealed insights from their own risk management experiences in this risky field. 🔵 We ended the day with a fascinating panel discussion led by Chaim Martin - Director of Business Development, with founders of portfolio companies David Reichman and Nissan Elimelech, who shared their personal journeys establishing healthech ventures. A big shout out to Chaim Martin for organizing the visit and ensuring that our fellowship cohort gained insights from so many aspects of the inspiring activities at aMoon. And many thanks to the entire team at aMoon for hosting us at such a challenging time, when efforts are laser focused on their mission to support the Israeli #biotech #healthtech ecosystem #NoMatterWhat. [Written by 3rd cohort fellow Dr. Einat Trugman Firestein 🙏]
-
-
-
-
-
+2
-
-
Congratulations to our aMoon Growth I portfolio company AltruBio Inc. for successfully raising an oversubscribed B round, allowing them to forge ahead with their Phase 2 program in Ulcerative Colitis. The Inflammation and Immunology space is a key focus area for aMoon, and AltruBio, targeting PSGL-1, is developing a first and best-in-class antibody to help patients who suffer from T-cell driven autoimmune disorders. Autoimmunity as a whole is a growing problem, increasing the need for therapies that are effective, safe, and don’t overly suppress the immune system. We would like to welcome our new partners RA Capital Management, Cormorant Asset Management, LP, and Soleus Capital Management, L.P., as well as returning investors, BVF PARTNERS, L.P and Blackstone. We would also like to thank AltruBio's stellar management team for all their efforts in both raising the capital and driving the clinical development forward - Dr. Judy Chou, Jesse W. Hall, and Jeroen Grasman Gur Roshwalb Avital Adler, PhD Todd Sone Tomer Berkovitz Yair Schindel, MD, MBA Yael Gruenbaum-Cohen Yaron Daniely
AltruBio Inc. today announced an oversubscribed Series B financing of up to $225 million to support ongoing and planned Phase 2 clinical trials of immune checkpoint enhancer, ALTB-268, in ulcerative colitis. Read the full press release here: https://bit.ly/3QSpI9U
-
-
Join us at #biomedisrael 2024! Yaron Daniely, Yael Gruenbaum-Cohen, and Avital Adler, PhD will be sharing insights at different sessions during the conference this week. #acceleratingcure #liquidbiopsy #womenshealth #geneticmedicine #biomed
-
-
We'll be at #ASGCT2024! Reach out to Tamar Farfel-Becker, Principal at aMoon Fund, if you'd like to connect. American Society of Gene & Cell Therapy
-
-
What makes an AI #drugdiscovery platform stand out? Osnat Hakimi and Roy Wiesner share an investor's viewpoint on how to identify the most promising technologies in the #AI and #machinelearning field below. Arik Kol Mati Gill Yair Benita Yaron Daniely Vered Gigi, PhD Tamar Farfel-Becker Noah Lasson #computationalbiology #bioinformatics
What Makes an AI-Drug Discovery Engine Stand Out
amoon.fund